Peptide-Drug Conjugates for Targeted Delivery in Hematological Malignancies: From Design Principles to Clinical...

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Hematological malignancies cause significant mortality, with relapse and drug resistance posing major challenges despite advanced therapies.
• Peptide-drug conjugates (PDCs) represent a promising targeted delivery strategy combining peptide specificity with cytotoxic payloads.

Purpose of the Study:

• To review the design principles of PDCs tailored for hematological malignancies.
• To examine the preclinical and clinical advancements of PDCs in various blood cancers.
• To discuss emerging strategies and translational challenges for precision PDC therapy.

Main Methods:

• Review of fundamental PDC design principles: targeting peptide selection, linker engineering, and payload optimization.
• Examination of current preclinical and clinical data for PDCs in multiple myeloma, AML, MDS, B-NHL, and CML.
• Discussion of novel approaches including PROTAC-PDC hybrids, nanotechnology, and AI-guided design.

Main Results:

• PDCs demonstrate potential in targeting diverse hematological malignancies, with ongoing preclinical and clinical investigations.
• Emerging strategies like PROTAC-PDC hybrids and AI-guided design show promise for enhanced efficacy.
• Key challenges include tumor heterogeneity, payload resistance, and pharmacokinetic limitations.

Conclusions:

• PDCs are a viable therapeutic strategy for hematological malignancies, offering targeted delivery and overcoming resistance mechanisms.
• Further research into advanced PDC designs and addressing translational hurdles is crucial for clinical success.
• Biomarker-driven precision therapy holds the key to optimizing PDC efficacy in blood cancers.